<DOC>
	<DOC>NCT02390258</DOC>
	<brief_summary>This study is an evaluation of the safety and tolerability of XEN-D0103 in healthy subjects. Part 1 assesses the safety, tolerability and blood levels of the ascending single doses of XEN-D0103. Blood levels of XEN-D0103 will be assessed when administered with food and also without food in Part 2. The safety, tolerability and blood levels of XEN-D0103 will be assessed following dosing for 10 days in Part 3.</brief_summary>
	<brief_title>Fed-Fasted, Single and Multiple Ascending Dose Trial of XEN-D0103</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>For Parts 1 and 3 healthy, male subjects aged 18 to 45 years, inclusive. For Part 2 healthy, male and female subjects aged 45 to 65 years, inclusive. Females must be of nonchildbearing potential Subject has a known heart disease. Subject has any of QTcF &gt; 450 msec, PR ≥ 210 msec or QRS ≥ 120 msec at screening (determined from median of three readings). For Part 1 only: subject has resting heart rate outside of the range 45 to 80 beats per minute (bpm) at screening (determined from median of three readings). Subject has any other condition which, in the investigator's opinion will interfere with the trial. Subject has a systolic blood pressure (BP) &lt;80 or &gt;160 mmHg at screening or a diastolic BP &gt;90 or &lt;45 mmHg at screening. Subject has a clinically significant abnormal laboratory test result at screening. Female subject who is pregnant or breast feeding and female subjects of childbearing potential.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>